QuEEN
Novartis Inks Second Molecular Glue Deal With Monte Rosa Worth Up to $5.7 Billion
Novartis; Monte Rosa Therapeutics; molecular glue degraders; $5.7 billion deal; drug discovery; immunology; QuEEN platform; autoimmune diseases; upfront payment; royalties; collaboration